About Us
OUR STORY
Havn Life is a part of a global community taking an active part in supporting research for microdosing therapies in treating mental health disorders utilizing psychedelics. Working with Veterans and thought leaders in the military, Havn Life is developing innovative formulations to support clinical trials addressing PTSD recovery and other trauma related disorders.
Through end to end research, extraction, formulation and delivery, we aspire to define and standardize the future of modern medicine. With an extensive team of industry leaders with 20+ years of experience in this space, Havn Life is formulating the next generation of medicine using psychedelic compounds.
MISSION
Our mission is to unlock human performance using evidence-informed research. We are focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from novel compounds.
Our Values
At Havn Life, we are dedicated to innovation, diversity and implementing the highest standards of the scientific method.
We have a deep-seated drive to help others and share our knowledge. With a range of standardized, quality-controlled formulated products, Havn Life will provide cutting edge technology and intellectual property for mental health and human performance with a strong focus on psychoactive natural healthcare products.
We believe in people and their potential and we envision a world where everyone is operating at peak mental performance and experience a considerable reduction in symptoms associated with mental illness.
Our Team
Collaboration across disciplines
Creating positive patient experiences and mental health outcomes
Vic Neufeld
Executive Chairman
CEO of Aphria for 5 years during large scale build up to one of the leading cannabis producers in the world.
Tim Moore
Chief Executive Officer
Former CEO of Green Growth Brands, from IPO through to Jan 2019, leading the Company to ~$1 Billion market cap.
Gary Leong
Chief Scientific Officer
Former Chief Scientific Officer at Aphria Inc. where he established and oversaw the Quality Assurance, Quality Control, Regulatory Affairs & Research and Development functions.
Dr. Ivan Casselman
Chief Psychedelic Officer
Extensive nutraceutical formulation experience, with several products available in legal cannabis markets in North America.
Alexzander Samuelsson
Chief Research Officer
Lead chemist of a publicly traded extraction company, Alexzander developed intellectual property and patented methods in the extraction of cannabis oils.
Eli Dusenbury
Chief Financial Officer
Served as a consultant for audit and public practice firms in both Canada and the US and has held CFO positions for publicly traded companies.
Juliana Mollica
Director of Innovation and Quality Assurance
Led projects as the quality assurance and compliance manager for cannabis and pharmaceutical companies to ensure maintenance of GMP requirements, developing QMS for multi-site projects, compliance training programs, and increasing compliance and quality rates.
Rick Brar
Vice Chairman
CEO & Chairman of Brains Bioceutical Corp. A global manufacturer and distributor of Cannabinoid API.
Tim Laidler
Director
Executive Director of the Institute for Veterans Education and Transition at UBC. The institute focuses on supporting the needs of veterans in the community as well as supporting cutting edge research with Veterans.
Dennis Staudt
Director
Financial and business expert. As CPA with 22 years as a partner in PricewaterhouseCooper's Audit and Assurance Group. Vice-President of a family-owned farming operation, Staudt Farms.
Dr. David Mokler
Advisor
Expert specialist in neuropharmacology, psychopharmacology, substance abuse, drug abuse, brain development, dopamine and serotonin including work relevant to the 5HT2a receptors in psychedelics
Sheila Copps
Advisor
The Honourable Sheila Copps was the first woman to ever hold the position of Deputy Prime Minister and served for ten years in the federal cabinet.
Allan Oberman
Advisor
Served as CEO for Concordia International, an international speciality pharmaceutical company with sales in 90 countries and over 200 medicines.
David King
Advisor
Drug science and policy expert who received the Dr Abbas Khan Medal by King’s College London for ‘outstanding humanitarian contributions to the service of society’. Also Founder of the Breaking Convention, Europe’s largest academic conference on psychedelic drug research.
Path To Market
regulated Route To Market
. . . . .
.
.
.
.
.
Direct To Consumers
Natural Health Products
. . . . .
.
.
.
.
.
Contract Manufacturer
(White Label)
Natural Health Products
.
.
.
.
.
Direct To Consumers
Contract Manufacturer
(White Label)
ReSTRICTED COMPOUND Route To Market
. . . . .
.
.
.
.
.
Supply Academic Research
(Dealers License)
Psychedelic Extraction and Supply
. . . . .
.
.
.
.
.
Formulate Microdosing Therapies
(Pre-Clinical Trials)
Psychedelic Extraction and Supply
.
.
.
.
.
Supply Academic Research
(Dealers License)
Formulate Microdosing Therapies
(Pre-Clinical Trials)
Mushroom Market
Demand for mushrooms is growing. The market for mushrooms such as Lion’s Mane, Cordyceps, Reishi, and Chaga is rising. These mushrooms have numerous benefits that we are still discovering today. Mushrooms are an extremely beneficial and nutritious functional food that will continue to be a key player in the global functional food market. The market is set to reach a value of $34.3 Billion USD by 2024.
Where Mushrooms Are Grown Matters
Mushrooms, even more than other foods, are a product of their environment. They absorb all pollution, pesticides, heavy metals, or even chemical waste that is present in the area they are grown. In 2017 it was estimated that over 85% of mushrooms coming into North America were imported and that these imported mushrooms contained dangerous amounts of illegal pesticide residue, added hormones, preservatives, and illegal fertilizers.
Growing Mushroom Market
Global Revenue in 2016 – 2024
The global functional food market is expected to reach $34.3 Billion USD by 2024, registering a CAGR of 8.04% during the forecast period (2019-2024)
The market studied is expected to experience huge demand for Reishi and Cordyceps and this is why Havn Life has decided to pursue formulations with these mushrooms.
Roadmap
2020
Havn Labs
Received First Health Canada License
2020
Havn Labs
Finalize Pre-Clinical Protocols for Compound Extraction and Supply
2021
Havn Retail
Manufacture & Distribute at Scale
2021
Havn Labs
Licensed Dealer Approval
2021
Havn Labs
Supply Clinical Trials with GMP Certified Natural Compounds
2021
Havn Labs
Formulate Psychedelic Therapies for Clinical Trials
2022+
Havn Retail
Expansion of Distribution Channels
2022+
Havn Labs
Publish Analytical Method Results